0001479290-23-000080.txt : 20230620 0001479290-23-000080.hdr.sgml : 20230620 20230620162504 ACCESSION NUMBER: 0001479290-23-000080 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230615 FILED AS OF DATE: 20230620 DATE AS OF CHANGE: 20230620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kolaja Carey OConnor CENTRAL INDEX KEY: 0001848717 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 231025433 MAIL ADDRESS: STREET 1: C/O REVANCE THERAPEUTICS, INC STREET 2: 1222 DEMONBREUN STREET, SUITE 1001 CITY: NASHVILLE STATE: TN ZIP: 37203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6157247755 MAIL ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 wf-form4_168729267524879.xml FORM 4 X0407 4 2023-06-15 0 0001479290 Revance Therapeutics, Inc. RVNC 0001848717 Kolaja Carey OConnor C/O REVANCE THERAPEUTICS, INC 1222 DEMONBREUN STREET, 20TH FLOOR NASHVILLE TN 37203 1 0 0 0 1 Common Stock 2023-06-15 4 M 0 2500 18.12 A 19061 D Common Stock 2023-06-15 4 S 0 2500 28.24 D 16561 D Stock Option (Right to buy) 18.12 2023-06-15 4 M 0 2500 0 D 2032-05-03 Common Stock 2500.0 8256 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 16, 2023 by Ms. Kolaja. The shares subject to the stock option vested on May 4, 2023. /s/ Dwight Moxie, Attorney-in-Fact 2023-06-20